DONATE

Research news

IBEC participates in an international study to stop coronavirus contagion

Researchers at the Institute of Bioengineering of Catalonia (IBEC) led by Professor ICREA Núria Montserrat are studying the role of the receptor ‘Angiotensin converting enzyme’ (ACE2), one of the pathways that the SARS-Co-V2 virus uses to enter our body.

To do this, experts use mini-kidneys, as well as other cell cultures such as cardiac organoids. The goal is to exploit these mini-organs to better understand how the virus works.

Researchers at IBEC provide new insights on how to treat chronic infections

Researchers at Institute for Bioengineering of Catalonia (IBEC) have managed to recreate the coculture conditions and environmental requisites that would allow the simultaneous and stable growth of Pseudomonas aeruginosa and Staphylococcus aureus, two major pathogens commonly found growing together in intricate biofilms in disease-affected lungs or wounds.

Most chronic infections occur due to the inherent capacity of some bacterial pathogens to grow in biofilms. Biofilm-associated infections, which have become a critical worldwide threat, have historically been treated as single-species events.

Identified a new repairing mechanism of the peripheral nervous system by applyting bioengineering techniques

The Molecular and cellular neurobiotechnology group with the collaboration of the Nanobioengineering group, both of them at IBEC, have applied a new light-stimulated technique to modulate muscular activity and stimulate cell regeneration of the peripheral nervous system.

Thanks to this research they have discovered that muscle activity can activate the neurons and accelerate their regeneration after an injury.

Researchers at IBEC track how pathogens adapt to oxygen changes

The Bacterial Infections: Antimicrobial Therapies group at IBEC, led by Eduard Torrents, has developed a system capable of investigating how pathogens adapt to oxygen changes.

Using this technique, they have discovered that bacteria E. coli and Pseudomonas aeruginosa can adapt to environmental changes through different mechanisms, which opens the door to better knowledge and treatment of infections.

New advances in the improvement of the design of drugs against glial globular tauopathy

José Antonio del Río, principal investigator at the Institute for Bioengineering of Catalonia (IBEC) together with Dr. Isidre Ferrer from Bellvitge Biomedical Research Institute (IDIBELL) led a study where they have unraveled that the pathology shown by patients with Globular Glial Tauopathy is due to the generation of harmful protein deposits for neurons and glial cells.

Tauopathies are characterized by the accumulation of phosphorylated tau protein, that associates with phosphate groups.

A research team develop biotransistors able to hear small beats of live

Researchers at IBEC and ICMAB develop a flexible, cheap and biocompatible transistor platform able to record an electrocardiogram of cells and micro-tissues during long periods of time.

The platform, based on organic transistor technology (EGOFET), can also measure the effect of drugs on beating cells, as cardiomyocytes, opening the door to several applications such as implantable devices for health.

IBEC bioengineers contribute to a heart implant

A group from the Institute for Bioengineering of Catalonia (IBEC) led by Daniel Navajas contributes to an operation designed to repair the heart tissue of a 70-year-old patient who had suffered a heart attack. This was made possible by the creation of a bioimplant enriched with stem cells. The operation is the result of the joint work of scientists, doctors and engineers over more than ten years.

Joan Montero and colleagues in Boston suggest a new strategy for melanoma patients

IBEC researcher Joan Montero authors a paper in Nature Communications which uncovers a key adaptation that melanoma cancer cells use to evade current therapies. This finding might allow physicians to use better drug combinations to improve patient outcomes in the future.

Despite significant advances in cancer diagnosis and treatment, most targeted cancer therapies fail to achieve complete tumor regressions or durable remission. Understanding why these treatments are not always efficient has remained a main challenge for researchers and physicians. Now, Joan Montero from the IBEC and colleagues at Dana-Farber Cancer Institute/Harvard Medical School in USA report in Nature Communications a mechanism that uncovers why some therapies fail to treat melanoma.

New advances in the treatment of advanced lung cancer

A research team led by Jordi Alcaraz, tenure track-2 lecturer from the Department of Biomedicine of the Faculty of Medicine and Health Sciences of the University of Barcelona and research associated at the Institute for Bioengineering of Catalonia (IBEC), in collaboration with the Hospital Clínic de Barcelona and the Boehringer Ingelheim company, has identified the molecular mechanisms than could have implications in the design of new therapeutic strategies to expand the clinical benefits of a drug to a larger spectra of patients with lung cancer.

A smartphone for detecting sleep apnea at home

The Biomedical signal processing and interpretation group at the Institute for Bioengineering of Catalonia (IBEC) has developed a portable, cheap and non-invasive system to detect obstructive sleep apnea (OSA) at home, a disorder characterized by recurrent airflow cessation during sleep. Researchers propose a novel method consisting of analyzing acoustic signals recorded with a smartphone.

Sleeping, like breathing, is an action that we all undertake throughout our whole lives. Sleep, which represents more than 25% of our time, is the body’s natural state of rest and an important factor of self-regulation. However, several diseases can affect sleep quality, leading to symptoms of varying severity.